Clinical-stage biotherapeutics company developing proprietary compounds inspired by proteoglycans to target the extracellular matrix (ECM)
Clinical-stage biotherapeutics company developing proprietary compounds inspired by proteoglycans to target the extracellular matrix (ECM). Its lead candidate, SB-030, is a locally applied treatment intended to reduce inflammation and vessel scarring after vascular interventions for peripheral artery disease.